NORTHWEST BIOTHERAPEUTICS INC
NWBO · OTCMCIK 1072379fmd_082G8SR4K7A9F08SSAR02PX30M制造业 · 医药制剂模板: 标准
覆盖范围: 1996年1月02日 至 2026年9月30日，共 80 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | 1 | 0 | 0 | 2 | 1 | 1 | 2 | 2 | 1 | 1 |
| 营业成本 | – | – | – | – | – | – | – | – | – | – |
| 毛利润 | – | – | – | – | – | – | – | – | – | – |
| 研发费用 | 60 | 34 | 18 | 14 | 34 | 20 | 36 | 28 | 35 | 29 |
| 营业利润 | (79) | (55) | (41) | (28) | (87) | (53) | (67) | (56) | (67) | (60) |
| 利息费用 | 4 | 6 | 10 | 3 | 9 | 5 | 6 | 5 | 8 | 9 |
| 利息及投资收益 | – | – | – | – | – | – | – | – | – | – |
| 其他营业外收入（支出） | – | (18) | 6 | 7 | (443) | 232 | (38) | (7) | (17) | (1) |
| 税前利润 | – | – | – | – | – | – | – | – | (84) | (61) |
| 所得税费用 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (1) |
| 持续经营净利润 | – | – | – | – | – | – | – | – | (84) | (60) |
| 净利润 | (80) | (73) | (36) | (21) | (530) | 179 | (105) | (63) | (84) | (60) |
| 归属于普通股股东的净利润 | (86) | (74) | (54) | (21) | (530) | 179 | (105) | (64) | (85) | (61) |